
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index includes publicly-issued U.S. Treasury securities that have a remaining maturity greater than or equal to seven years and less than or equal to ten years and have $300 million or more of outstanding face value, excluding amounts held by the Federal Reserve. The fund is non-diversified.
Is PST's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Lode Gold Resources Inc (TSXV: LOD) (OTCQB: LODFF) ("Lode Gold" or the "Company") is pleased to invite shareholders and interested investors to a coming technical webinar focused on the company's recent Mineral Resource Estimate ("MRE") news and update at its 100% owned Fremont Gold Mine ("Fremont") in Mariposa County, California. The webinar will feature a detailed technical presentation by Technical Advisor and Fremont Technical Lead, Carlos Saban and Gary Wong, P.Eng.

Presentation to be held at Las Vegas Bellagio Resort & Hotel on Wednesday June 17, 2026 at 11:00 a.m. PST Presentation to be held at Las Vegas Bellagio Resort & Hotel on Wednesday June 17, 2026 at 11:00 a.m. PST

VANCOUVER, British Columbia, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three months and year ended December 31, 2025. All dollar amounts are in US dollars ($).

Whether it's because you want to look at guaranteed income from your investments or you want to diversify your portfolio, dividends are becoming more of the norm for investors.

PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial.